Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lee Schwartzberg

Showing results (61-70 of 112) with videos related to

Pageof 12
Sort By:
Health Services Research|June 17, 2025
COVID-19-Related Financial Hardship and Adherence to Adjuvant Endocrine Therapy Among Women With Early-Stage Breast CancerSara Arshad, Xin Hu, Rebecca A Krukowski, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|December 19, 2023
2023 updated MASCC/ESMO consensus recommendations: controlling nausea and vomiting with chemotherapy of low or minimal emetic potentialIan Olver, Rebecca Clark-Snow, Christina H Ruhlmann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 20, 2006
Phase II trial of bexarotene capsules in patients with advanced non-small-cell lung cancer after failure of two or more previous therapiesRamaswamy Govindan, John Crowley, Lee Schwartzberg, et al.
JAMA Network Open|June 1, 2021
Characterization of Clinical Symptoms by Race Among Women With Early-Stage, Hormone Receptor-Positive Breast Cancer Before Starting ChemotherapyXin Hu, Puneet K Chehal, Cameron Kaplan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 11, 2009
Adjuvant therapy with the monoclonal antibody Edrecolomab plus fluorouracil-based therapy does not improve overall survival of patients with stage III colon cancerAnthony L A Fields, Alan Keller, Lee Schwartzberg, et al.
Journal of Circulating Biomarkers|October 8, 2024
A novel liquid biopsy assay for detection of <i>ERBB2</i> (HER2) amplification in circulating tumor cells (CTCs)Giuseppe Di Caro, Ernest T Lam, David Bourdon, et al.
Journal of Pain and Symptom Management|April 15, 2003
The Zero Acceptance of Pain (ZAP) Quality Improvement Project: evaluation of pain severity, pain interference, global quality of life, and pain-related costsBarry V Fortner, Theodore A Okon, Jeri Ashley, et al.
Cancer Chemotherapy and Pharmacology|December 3, 2003
Interferon-gamma pharmacokinetics and pharmacodynamics in patients with colorectal cancerP Kellie Turner, Janet A Houghton, Istvan Petak, et al.
European Journal of Cancer (Oxford, England : 1990)|September 8, 2012
A double-blind, randomised, placebo-controlled, phase 2b study evaluating sorafenib in combination with paclitaxel as a first-line therapy in patients with HER2-negative advanced breast cancerWilliam J Gradishar, Virginia Kaklamani, Tarini P Sahoo, et al.
Breast (Edinburgh, Scotland)|August 13, 2021
Efficacy and safety of palbociclib in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with preexisting conditions: A post hoc analysis of PALOMA-2Karen Gelmon, Janice M Walshe, Reshma Mahtani, et al.
Pageof 12

Showing results (61-70 of 112) with videos related to

Sort By:
Pageof 12
Health Services Research|June 17, 2025
COVID-19-Related Financial Hardship and Adherence to Adjuvant Endocrine Therapy Among Women With Early-Stage Breast CancerSara Arshad, Xin Hu, Rebecca A Krukowski, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|December 19, 2023
2023 updated MASCC/ESMO consensus recommendations: controlling nausea and vomiting with chemotherapy of low or minimal emetic potentialIan Olver, Rebecca Clark-Snow, Christina H Ruhlmann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 20, 2006
Phase II trial of bexarotene capsules in patients with advanced non-small-cell lung cancer after failure of two or more previous therapiesRamaswamy Govindan, John Crowley, Lee Schwartzberg, et al.
JAMA Network Open|June 1, 2021
Characterization of Clinical Symptoms by Race Among Women With Early-Stage, Hormone Receptor-Positive Breast Cancer Before Starting ChemotherapyXin Hu, Puneet K Chehal, Cameron Kaplan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 11, 2009
Adjuvant therapy with the monoclonal antibody Edrecolomab plus fluorouracil-based therapy does not improve overall survival of patients with stage III colon cancerAnthony L A Fields, Alan Keller, Lee Schwartzberg, et al.
Journal of Circulating Biomarkers|October 8, 2024
A novel liquid biopsy assay for detection of <i>ERBB2</i> (HER2) amplification in circulating tumor cells (CTCs)Giuseppe Di Caro, Ernest T Lam, David Bourdon, et al.
Journal of Pain and Symptom Management|April 15, 2003
The Zero Acceptance of Pain (ZAP) Quality Improvement Project: evaluation of pain severity, pain interference, global quality of life, and pain-related costsBarry V Fortner, Theodore A Okon, Jeri Ashley, et al.
Cancer Chemotherapy and Pharmacology|December 3, 2003
Interferon-gamma pharmacokinetics and pharmacodynamics in patients with colorectal cancerP Kellie Turner, Janet A Houghton, Istvan Petak, et al.
European Journal of Cancer (Oxford, England : 1990)|September 8, 2012
A double-blind, randomised, placebo-controlled, phase 2b study evaluating sorafenib in combination with paclitaxel as a first-line therapy in patients with HER2-negative advanced breast cancerWilliam J Gradishar, Virginia Kaklamani, Tarini P Sahoo, et al.
Breast (Edinburgh, Scotland)|August 13, 2021
Efficacy and safety of palbociclib in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with preexisting conditions: A post hoc analysis of PALOMA-2Karen Gelmon, Janice M Walshe, Reshma Mahtani, et al.
Pageof 12